New study uncovers key role of microRNAs in blood clotting during severe COVID-19

Medical News: The COVID-19 pandemic continues to provide new insights into how the virus affects the body, and recent studies have highlighted the role of microRNAs (miRNAs) in influencing blood clotting and inflammation. A groundbreaking study conducted by researchers from the University of Helsinki and Helsinki University Hospital, along with the Minerva Foundation Institute for Medical Research in Finland, delves into this connection, providing critical information on how miRNAs impact coagulation in patients hospitalized with severe COVID-19. This Medical News report focuses on the study's findings, helping to explain how COVID-19 alters blood clotting mechanisms.


New study uncovers key role of microRNAs in blood clotting during severe COVID-19

Key Findings of the Study
COVID-19 has long been associated with blood clotting disturbances. However, data on the role of miRNAs in this process has been scarce. The research team studied blood samples from 40 patients hospitalized due to severe COVID-19. The study included both men and women, with the median age being 51 years. The researchers aimed to uncover the relationship between miRNAs and coagulation markers such as von Willebrand factor (VWF) and platelet count. Using advanced PCR techniques, the team was able to analyze 27 miRNAs linked to thrombosis and platelet activation, comparing their levels in COVID-19 patients with 10 healthy controls.
 
The researchers found that several miRNAs, including miR-27b-3p, miR-320a-3p, and miR-424-5p, were significantly higher in COVID-19 patients compared to the controls. In contrast, miR-103a-3p and miR-145-5p levels were lower. These miRNAs were found to be involved in crucial processes such as blood clotting, inflammation, and fibrinolysis (the process that prevents blood clots from growing too large). According to the researchers, these changes in miRNA expression could help explain why COVID-19 leads to increased blood clotting in some patients, which is often associated with more severe outcomes.
 
The Role of miRNAs in Blood Clotting
MicroRNAs are tiny molecules that regulate gene expression, playing critical roles in various biological processes, including blood clotting and inflammation. The study revealed that miRNAs like miR-27b-3p and miR-320a-3p are key players in enhancing coagulation in COVID-19 patients. These miRNAs were shown to target genes involved in fibrinolysis inhibition and increased platelet activation.
 
In particular, miR-27b-3p was found to target genes associated with plasminogen, a protein crucial for breaking down blood clots. Higher levels of miR-27b-3p could, therefore, inhibit fibrinolysis, leading to an increased risk of blood clots. Similarly, miR-320a-3p was associated with platelet activation, which can lead to the formation of blood clots in COVID-19 patients. The researchers also observed that patients with higher VWF levels, a marker of coagulation, had increased levels of miRNAs such as miR-24-3p, miR-126-3p, and miR-145-5p.
 
Inflammation and Coagulation Interplay
T he study also highlighted the role of inflammation in driving changes in miRNA levels. COVID-19 is known to trigger an inflammatory response, and this study found that certain miRNAs, such as miR-145-5p, are associated with both inflammation and blood clotting. While miR-145-5p levels were lower in COVID-19 patients compared to healthy controls, the study noted that this miRNA was linked to increased platelet count and VWF levels in more severely ill patients. This suggests that miR-145-5p may be involved in the complex interplay between inflammation and coagulation in COVID-19 patients.
 
Interestingly, let-7b-3p, another miRNA, was associated with low hemoglobin levels, indicating its potential role in anemia, which is commonly observed in COVID-19 patients. This finding is particularly relevant because anemia and increased coagulation have both been linked to poorer outcomes in COVID-19.
 
miRNA as Potential Biomarkers
One of the study’s most promising findings is the potential of miRNAs as biomarkers for predicting COVID-19 severity. By analyzing the levels of specific miRNAs in hospitalized patients, healthcare providers may be able to predict which patients are at a higher risk of developing severe complications related to blood clotting. The miRNAs miR-27b-3p, miR-320a-3p, and miR-424-5p emerged as key candidates for future biomarker research. These miRNAs showed consistent associations with increased coagulation activity, suggesting that they could be useful for identifying patients who might benefit from anticoagulant therapies.
 
Additionally, the study found a strong correlation between miR-103a-3p levels and anti-Xa activity, a marker of the effectiveness of blood-thinning medications like heparin. This suggests that miRNA profiling could also help monitor the effectiveness of treatments in COVID-19 patients, offering a more personalized approach to managing the disease.
 
Study Limitations and Future Research
While the study provides valuable insights, it is not without limitations. One significant limitation is the relatively small sample size, which limits the ability to generalize the findings to all COVID-19 patients. The researchers also pointed out that pre-COVID-19 blood samples were not available, making it difficult to determine whether the observed changes in miRNA levels were directly caused by the virus or were pre-existing conditions in some patients.
 
Future research will need to focus on larger patient cohorts and include more detailed clinical data to validate these findings. Understanding how miRNAs interact with other molecular pathways in COVID-19 patients will be essential for developing targeted therapies that can prevent the severe blood clotting complications often seen in the disease.
 
Conclusion
In conclusion, this study sheds light on the crucial role of miRNAs in regulating blood clotting and inflammation in COVID-19 patients. The findings reveal that certain miRNAs are significantly altered in patients with severe COVID-19, affecting both coagulation and fibrinolysis processes. These discoveries not only deepen our understanding of the complex relationship between COVID-19 and blood clotting but also pave the way for using miRNAs as potential biomarkers for predicting disease severity.
 
The study findings were published in the peer-reviewed Thrombosis Journal.
https://link.springer.com/article/10.1186/s12959-024-00649-w
 
For the latest COVID-19 News, keep on logging to Thailand Medical News.
 
Read Also:
https://www.thailandmedical.news/news/new-study-reveals-key-differences-in-mirna-expression-between-long-covid-and-recovered-patients
 
https://www.thailandmedical.news/news/covid-19-news-exosomal-mirnas-and-their-implications-in-covid-19-related-acute-respiratory-distress-syndrome-sequelae